In Guinea-Bissau, children were randomised at 6 months of age to receive either two doses of standard-titre measles vaccine at 6 and 9 months of age or an inactivated polio vaccine at 6 months and standard-titre measles vaccine at 9 months of age. During the first 5 months, children received Edmonston-Zagreb (EZ) vaccine and during the following 11 months, the Schwarz (SW) vaccine. Five percent of the mothers, 74% of children at 6 months of age, and 92% of unvaccinated children at 9 months of age had unprotective levels (<125 mIU/ml) of measles antibodies. Among children receiving EZ vaccine, 1% were unprotected at 18 months of age after either two (3/240) or one (3/211) doses of vaccine, the geometric mean measles antibody titre (GMT) being approximately 1550 mIU/ml in both groups. Among those receiving SW vaccine 9% (34/365) and 3% (9/310) were unprotected at 18 months of age in the two-dose and the one-dose groups (RR = 3.21 (95% confidence interval (CI) 1.56-6.58)), respectively. The GMT was higher after one dose of SW vaccine at 9 months of age (2491 mIU/ml) than after two doses of SW vaccine (1125 mIU) (P < 0.001). In the EZ vaccine group, there was no significant difference in antibody level for children vaccinated in the presence of high or low levels of maternal antibodies, whereas there was a marked difference in the SW group. The second EZ vaccine induced a significant antibody increase between 9 months of age (1191 mIU) and 18 months of age (1602 mIU, P=0.011), whereas antibody levels tended to decline from 9 months (1243 mIU) to 18 months of age (998 mIU, P = 0.124) after the second dose of SW vaccine. Conclusively, after two doses of EZ measles vaccine more children were protected at 18 months of age than after two doses of SW. One dose of SW provided the highest antibody response, but a higher proportion of unprotected than one or two doses of EZ. The EZ vaccine was less sensitive to maternal antibodies, and able to increase the antibody response by revaccination, while the second SW vaccine resulted in an unchanged or lower antibody response.

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0264-410x(00)00431-xDOI Listing

Publication Analysis

Top Keywords

months age
20
vaccine months
16
standard-titre measles
12
measles vaccine
12
edmonston-zagreb vaccine
8
months
8
children months
8
vaccine
7
age
5
measles
4

Similar Publications

In this study, we first analyzed data from 147 patients with solitary plasmacytomas treated at the Mayo Clinic between 2005 and 2022 and then expanded our investigation through a systematic review and meta-analysis of 62 studies, encompassing 3,487 patients from the years 1960 to 2022. Our findings reveal that patients with up to 10% clonal plasma cells in their bone marrow (BM), denoted as plasmacytoma +, had a significantly reduced median disease-free survival (DFS) of 15.7 months vs.

View Article and Find Full Text PDF

State-Level Influenza Hospitalization Burden in the United States, 2022-2023.

Am J Public Health

January 2025

Alexia Couture, A. Danielle Iuliano, Ryan Threlkel, Matthew Gilmer, Alissa O'Halloran, Dawud Ujamaa, Matthew Biggerstaff, and Carrie Reed are with the National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA. Howard H. Chang is with the Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, GA.

To develop a method leveraging hospital-based surveillance to estimate influenza-related hospitalizations by state, age, and month as a means of enhancing current US influenza burden estimation efforts. Using data from the Influenza Hospitalization Surveillance Network (FluSurv-NET), we extrapolated monthly FluSurv-NET hospitalization rates after adjusting for testing practices and diagnostic test sensitivities to non-FluSurv-NET states. We used a Poisson zero-inflated model with an overdispersion parameter within the Bayesian hierarchical framework and accounted for uncertainty and variability between states and across time.

View Article and Find Full Text PDF

Purpose: To analyze survival and its predictors among patients with hepatocellular carcinoma (HCC) receiving transarterial chemoembolization (TACE) in Ethiopia.

Materials And Methods: We conducted a retrospective cohort study among patients who received TACE for HCC at MCM Hospital from December 1, 2016, to December 31, 2022. Data were extracted from patients' medical records, and vital status was ascertained from the patients' charts or by phone call to the next of kin.

View Article and Find Full Text PDF

Purpose: Prior noncontemporary studies showed that oral cyclophosphamide is an active treatment of metastatic castration-resistant prostate cancer (mCRPC). However, cyclophosphamide is currently underutilized in routine clinical practice given the lack of survival benefit and the emergence of more effective treatments.

Methods: We retrospectively reviewed our institutional database to identify patients with mCRPC treated with cyclophosphamide.

View Article and Find Full Text PDF

Purpose: Pancreatic cancer is one of the deadliest cancers in the world. In Armenia, it is 12th by incidence. The aim of this study is to evaluate treatment and outcomes of pancreatic cancer in Armenia during the past 12 years.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!